Gemigliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used for the treatment of type 2 diabetes. It is primarily used to control high blood sugar levels. The rising global diabetic population due to sedentary lifestyle and unhealthy eating habits has increased the demand for effective anti-diabetic drugs.
The global Gemigliptin Market is estimated to be valued at US$ 1.79 Bn in 2024 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing diabetic population has accelerated the growth of the gemigliptin market. As per the International Diabetes Federation (IDF), around 463 million adults aged between 20-79 years were living with diabetes in 2019, and this number is expected to rise to 578 million by 2030 and 700 million by 2045. Since diabetes leads to various severe complications such as kidney damage, blindness, and amputation if left uncontrolled, patients require effective glucose-lowering therapies like DPP-4 inhibitors. Gemigliptin is a highly selective DPP-4 inhibitor, which maintains long-lasting plasma active concentration and provides effective glycemic control. Therefore, its demand is expected to grow considerably over the forecast period owing to the rising prevalence of diabetes globally.
The global Gemigliptin market is dominated by oral solid dosage sub segment mainly tablets. It accounts for around 75% of the total market share owing to ease of consumption and better stability of drugs in solid form compared to liquids. This ensures compliance to treatment as well.
The Global Gemigliptin Market Share is expected to witness high growth over the forecast period 2023 to 2030. The global Gemigliptin Market is estimated to be valued at US$ 1.79 Bn in 2024 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030.
Regional analysis related content comprises Asia Pacific region is expected to witness fastest growth in the Gemigliptin market owing to rising prevalence of Type 2 diabetes in the region.
Key players operating in the Gemigliptin market are Samsung, Apple Inc., Microsoft Corporation, Mozo Accessories, iLuv Creative Technology, Energizer, Case-mate, and Muvit. The key players are focusing on new product launches and strategic collaborations to gain maximum share in the market and reach a wider customer base.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it